NLS Pharmaceutics AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NLSP research report →
Price Chart
About the company
NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD.
- CEO
- Alexander Zwyer
- IPO
- 2021
- Employees
- 6
- HQ
- Zurich, CH
Get TickerSpark's AI analysis on NLSP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $919.60K
- P/E
- -0.37
- Fwd P/E
- 0.06
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 1.57
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 41.94%
- ROIC
- -75.27%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-3,321+70.9%
- Op Income
- $-4,380,113
- Net Income
- $-1,980,810+83.7%
- EPS
- $-26.30-721.9%
- OCF Growth
- +55.9%
- FCF Growth
- +55.9%
- 52W High
- $43.40
- 52W Low
- $0.76
- 50D MA
- $18.99
- 200D MA
- $19.40
- Beta
- 0.13
- RSI (14)
- 20
- Avg Volume
- 74.12K
No earnings-call transcripts are available for NLSP yet.
- Free Float
- 63.0%
- Shares Outstanding
- 316.01K
- Float Shares
- 199.17K
of shares held by institutions
1 13F filers
Our NLSP coverage
Recent articles, reports, and earnings notes.
No research on NLSP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NLSP report →NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.
prnewswire.com · Nov 3
NLS Pharmaceutics Ltd. and Kadimastem Ltd.
prnewswire.com · Oct 30
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
prnewswire.com · Oct 30
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
prnewswire.com · Oct 29
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
prnewswire.com · Oct 29
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
prnewswire.com · Oct 29
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
prnewswire.com · Oct 27
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
prnewswire.com · Oct 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.